Wegovy could be offered to cut heart attack and stroke risk

A treatment option – GLP-1 drug semaglutide known as Wegovy – is set to be available on the NHS within months, with 1.2 million people with cardiovascular disease eligible to receive the treatment to help prevent heart attacks and strokes over the next few years. People with heart and circulatory disease who are overweight will be able to receive the drug in England from this summer, following approval by the National Institute for Health and Care Excellence.

Keep up to date

Sign up to receive our daily news alerts straight to your inbox. Subscribe to our weekly newsletter containing a summary of the week’s news, blog and vote on our poll.

Weekly Newsletter

Daily news updates

Have a discussion

Help keep the conversation going between meetings by creating a forum to hold discussions with your members. It’s an easy way to manage and communicate with members.

Create a network

Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.

Networks can be open to all or available only to a closed group defined by the administrator.

Join or create a network here.